Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.
Bone Marrow Transplant. 2011 Oct;46(10):1339-44. doi: 10.1038/bmt.2010.294. Epub 2011 Jan 17.
Our purpose was to assess efficacy and toxicity of high-dose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg+ melphalan 160 mg/m(2)) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73% (95% confidence interval (CI) 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P=0.45); OS after ASCT was 88% (95% CI 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P=0.80). No transplant-related deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.
我们的目的是评估大剂量化疗（HDCT）和 ASCT 在 60 岁及以上复发/难治性霍奇金淋巴瘤（HL）患者中的疗效和毒性，并将结果与一组接受类似治疗的年轻 HL 患者进行比较。我们确定了 15 例连续患者，这些患者均为 60 岁及以上的 HL，于 2001 年 5 月至 2008 年 3 月在我院接受 HDCT（依托泊苷 60mg/kg+美法仑 160mg/m2）和 ASCT。结果与 1999 年 1 月至 2006 年 12 月期间接受类似治疗的一组 157 例年轻 HL 患者进行了比较。在中位随访 2.5 年后，ASCT 后 3 年的 PFS 为老年组 73%（95%CI 37-90），年轻组 56%（95%CI 46-64）（P=0.45）；ASCT 后 OS 为老年组 88%（95%CI 39-98），年轻组 84%（95%CI 75-90）（P=0.80）。未观察到移植相关死亡。我们的研究表明，ASCT 对选择的老年 HL 患者是可行的，在生存和毒性方面与年轻患者相似。
